Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
9th June 2026 Uncategorised 0
SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments

More: Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
Source: News
